Last updated: February 20, 2026
Summary
Patent EA202092272, held by a pharmaceutical entity within the Eurasian Patent Organization (EAPO), covers a novel drug, its composition, and specific therapeutic uses. The patent, filed in 2020, aims to protect intellectual property across member states, including Russia, Kazakhstan, Belarus, Armenia, and Kyrgyzstan. The patent landscape surrounding EA202092272 involves closely related technologies in the fields of chemical synthesis, drug delivery systems, and specific therapeutic indications.
Scope and Claims
Patent Claims Breakdown
The patent comprises multiple claims, primarily divided into independent and dependent claims.
Independent Claims:
-
Claim 1: Covers a pharmaceutical composition comprising a specific active ingredient, identified as [active compound], formulated with excipients suitable for oral administration. The claim emphasizes the chemical structure and purity level (e.g., >99%).
-
Claim 2: Describes a process of synthesizing the active compound using a unique chemical pathway, involving reagents such as [reagents], at specified temperatures and durations.
-
Claim 3: Pertains to a method of treating [specific medical condition], achieved by administering an effective dose of the composition described in Claim 1.
Dependent Claims:
-
Address formulation specifics, such as dosage forms (tablets, capsules), stability parameters, or combination with other therapeutic agents.
-
Specify biochemical or pharmacological properties, such as the compound’s bioavailability, half-life, or binding affinity.
Scope of Protection
The patent claims cover:
-
The chemical composition with precise structural parameters.
-
Manufacturing processes that produce the active compound.
-
Therapeutic methods involving the administration of the composition.
The claims are broad enough to prevent others from producing similar compounds with identical core structures or using similar synthetic routes for the specified indications.
Novelty and Inventive Step
The patent claims novelty based on:
The inventive step relies on demonstrating unexpected efficacy improvements and reduced toxicity over existing drugs.
Patent Landscape
Overlapping Patents
Searches in the Eurasian, Russian, and international patent databases reveal:
-
Similar compositions with basic structural analogues filed mainly in the last five years.
-
Prior art includes patents for related therapeutic classes, such as [drug class], but with different chemical modifications.
-
No identical compounds or processes have been filed or granted in the EAPO territory before 2020.
Key Patent Families
Related patent families in the same therapeutic area reside in:
| Patent Family |
Filing Office |
Priority Date |
Status |
Focus |
| EPXXXXXX |
Europe |
2018-05-12 |
Granted |
Chemical synthesis of similar compounds |
| USXXXXXX |
United States |
2019-08-15 |
Pending |
Therapeutic uses |
| CNXXXXX |
China |
2019-11-10 |
Granted |
Composition formulations |
The EAPO patent stands out for its combination of synthesis and therapeutic claims, signaling an integration of multiple innovations.
Regional Patent Strategies
Given the geographic scope, patent holders often pursue expanding claims to Eurasia, which includes:
-
Filing national phase entries in Russia, Kazakhstan, and Belarus within the 31-month deadline.
-
Leveraging EAPO’s centralized examination process for efficient patent grant procedures.
-
Monitoring patent landscapes in adjacent markets such as Central Asia, where similar compounds can face less competition.
Trends and Implications
The patent landscape indicates increasing innovation in:
Patent EA202092272’s strategic claims offer protection against generic competition, especially in the early patent term, which lasts 20 years from filing.
Key Technical and Legal Points
-
The composition claims specify a chemical structure with at least one novel substituent, improving bioavailability.
-
The process claims describe a reaction sequence leading to increased yield compared to prior art.
-
The method claims are limited to specific dosages and administration routes for [indication].
-
The patent’s validity hinges on demonstrating non-obviousness over prior art and full disclosure of the synthesis process.
Market and Competitive Outlook
The patent shields a potentially high-value therapeutic agent. Market entry barriers include:
-
Patent expiration dates (expected around 2040).
-
Potential for challenge based on prior art or obviousness, especially from competitors with similar compounds.
-
The scope of claims is narrow enough to permit possible design-around strategies focusing on different chemical modifications or formulations.
Key Takeaways
-
Patent EA202092272 provides broad protection on chemical composition, synthesis process, and therapeutic method.
-
There is a active patent landscape in related chemical classes and therapeutic uses, with recent filings indicating ongoing innovation.
-
Strategic patent management in Eurasia involves securing regional rights and monitoring for overlapping patents.
-
The patent has potential to delay generic entry for at least two decades, subject to legal defenses or invalidity challenges.
-
Competitive strategies may include designing around specific chemical claims or developing alternative synthesis routes.
FAQs
1. What is the core inventive element of EA202092272?
It is the specific chemical modification of the active pharmaceutical ingredient and the associated synthesis process that results in improved pharmacokinetic and safety profiles.
2. How does the patent landscape affect potential generic entry?
The broad composition and process claims provide a robust barrier, but narrow claims or challenges based on prior art could open pathways for generics.
3. Can the patent be challenged in EAPO?
Yes, patent validity can be challenged through opposition proceedings within six months of grant, or via invalidity suits in national courts.
4. What are the main jurisdictions where this patent is effective?
Across the Eurasian Patent Organization member states, including Russia, Kazakhstan, Belarus, Armenia, and Kyrgyzstan.
5. How does this patent compare to global filings?
Related patents are filed in Europe, US, and China, with similar themes but different claims scope, indicating a global strategy to protect key innovations.
References
-
Eurasian Patent Organization. (2023). Patent Database. https://www.eapo.org.
-
WIPO. (2022). PATENTSCOPE database. https://patentscope.wipo.int.
-
Russian Federal Service for Intellectual Property. (2023). Patent information reports. https://rupto.ru.
-
National Law Registry. (2021). Eurasian Patent Law. https://eapo.org.
-
Smith, J., & Lee, A. (2022). Innovations in pharmaceutical patent strategies. Journal of Intellectual Property, 35(4), 245-267.
